Rock Springs Capital Management LP Invests $10.95 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

Rock Springs Capital Management LP acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 204,466 shares of the company's stock, valued at approximately $10,947,000. Rock Springs Capital Management LP owned approximately 0.39% of Janux Therapeutics as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its position in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after buying an additional 599 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of Janux Therapeutics by 7.9% during the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company's stock valued at $681,000 after acquiring an additional 928 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of Janux Therapeutics by 5.8% during the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock worth $926,000 after acquiring an additional 949 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Janux Therapeutics by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after purchasing an additional 1,095 shares during the period. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Stock Performance

Shares of NASDAQ:JANX traded down $1.02 during midday trading on Friday, hitting $31.05. 418,812 shares of the stock were exchanged, compared to its average volume of 851,671. The company has a market capitalization of $1.84 billion, a PE ratio of -26.54 and a beta of 3.27. Janux Therapeutics, Inc. has a 52-week low of $22.52 and a 52-week high of $71.71. The business's fifty day simple moving average is $30.08 and its two-hundred day simple moving average is $43.13.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on JANX. Wedbush reaffirmed an "outperform" rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Scotiabank decreased their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Finally, Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Janux Therapeutics presently has an average rating of "Buy" and an average price target of $95.25.

Insider Activity

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $30.00, for a total transaction of $100,020.00. Following the completion of the sale, the insider now owns 82,139 shares of the company's stock, valued at $2,464,170. This represents a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was purchased at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the transaction, the director now owns 9,658,988 shares of the company's stock, valued at approximately $295,951,392.32. This trade represents a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 10,002 shares of company stock worth $348,203. 29.40% of the stock is owned by corporate insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.